Arch Biopartners Awarded NRC-IRAP Funding to Further Develop Metablok Drug Program
TORONTO, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that the National Research Council – Industrial Research Assistance Program (“NRC-IRAP”) has approved funding totaling $200,000 for Arch scientists to further develop the Metablok (LSALT peptide) program. Metablok is the Company’s lead drug candidate for treating acute kidney injury and other organs damaged by inflammation.
The NRC-IRAP funds will be used to advance the drug library that is now emerging at Arch as a result of the initial development of Metablok.
TORONTO, Jan. 29, 2019 -- Arch Biopartners Inc., PRESS RELEASE FOR IMMEDIATE DISTRIBUTION
TORONTO, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has closed the non-brokered, unsecured convertible note (“Note”) financing it disclosed in a press release on January 24, 2019 for gross proceeds of CAD $500,000 (the “Offering”).
The Note matures on January 24, 2022 and will be convertible, at the option of the holder, into common shares in the capital of the Company (“Common Shares”) at a price per Common Share of $1.27, in the thirty-day period prior to the maturity of the Note.
TORONTO, Jan. 24, 2019 -- Arch Biopartners Inc., PRESS RELEASE FOR IMMEDIATE DISTRIBUTION
Toronto, Canada - Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has arranged a non-brokered, unsecured convertible note (“Note”) financing for gross proceeds of CAD $500,000 (the “Offering”).
The Note matures on January 24, 2022 and will be convertible, at the option of the holder, into common shares in the capital of the Company (“Common Shares”) at a price per Common Share of $1.27, in the thirty-day period prior to the maturity of the Note.